Brooktree Capital Management Has $650,000 Stock Holdings in Cardlytics, Inc. (NASDAQ:CDLX)

Brooktree Capital Management increased its holdings in shares of Cardlytics, Inc. (NASDAQ:CDLXFree Report) by 4.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 175,210 shares of the company’s stock after purchasing an additional 7,568 shares during the period. Cardlytics makes up about 0.5% of Brooktree Capital Management’s holdings, making the stock its 21st biggest position. Brooktree Capital Management owned 0.34% of Cardlytics worth $650,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Atom Investors LP bought a new position in shares of Cardlytics during the 3rd quarter worth about $33,000. Tallon Kerry Patrick bought a new position in Cardlytics in the fourth quarter worth approximately $37,000. Intech Investment Management LLC bought a new position in Cardlytics in the third quarter worth approximately $47,000. BNP Paribas Financial Markets grew its stake in Cardlytics by 32.1% in the third quarter. BNP Paribas Financial Markets now owns 19,745 shares of the company’s stock valued at $63,000 after acquiring an additional 4,796 shares during the period. Finally, Quadrature Capital Ltd bought a new stake in shares of Cardlytics during the third quarter valued at approximately $63,000. 68.10% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

CDLX has been the topic of a number of recent research reports. Needham & Company LLC reiterated a “hold” rating on shares of Cardlytics in a report on Thursday, March 13th. Evercore ISI reduced their price objective on shares of Cardlytics from $4.00 to $3.00 and set an “in-line” rating for the company in a report on Thursday, March 13th. Finally, Lake Street Capital lowered their target price on shares of Cardlytics from $5.00 to $3.00 and set a “hold” rating on the stock in a report on Thursday, March 13th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $6.42.

Get Our Latest Research Report on Cardlytics

Cardlytics Stock Down 3.6 %

Cardlytics stock opened at $2.38 on Tuesday. The company has a debt-to-equity ratio of 2.40, a quick ratio of 1.18 and a current ratio of 1.18. The stock has a market cap of $120.96 million, a PE ratio of -0.39 and a beta of 1.62. Cardlytics, Inc. has a fifty-two week low of $1.77 and a fifty-two week high of $20.52. The firm’s 50-day simple moving average is $2.97 and its 200 day simple moving average is $3.48.

Insider Transactions at Cardlytics

In other Cardlytics news, CFO Alexis Desieno sold 24,778 shares of the business’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $3.40, for a total value of $84,245.20. Following the transaction, the chief financial officer now owns 140,948 shares of the company’s stock, valued at approximately $479,223.20. The trade was a 14.95 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Amit Gupta sold 46,857 shares of the company’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $3.40, for a total value of $159,313.80. Following the completion of the transaction, the chief executive officer now owns 418,637 shares of the company’s stock, valued at $1,423,365.80. This trade represents a 10.07 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 111,454 shares of company stock worth $391,864 in the last 90 days. Insiders own 4.40% of the company’s stock.

Cardlytics Profile

(Free Report)

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.

Featured Stories

Want to see what other hedge funds are holding CDLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cardlytics, Inc. (NASDAQ:CDLXFree Report).

Institutional Ownership by Quarter for Cardlytics (NASDAQ:CDLX)

Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.